In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc….
eTurboNews artikel hanya untuk pelanggan. Berlangganan adalah KONSULTASI.
Pelanggan masuk di sini Klik di sini untuk berlangganan GRATIS
Pelanggan masuk di sini Klik di sini untuk berlangganan GRATIS
APA YANG PERLU DIPERHATIKAN DARI PASAL INI:
- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc….
- .
- eTurboNews artikel hanya untuk pelanggan.
